World’s First AI-Native Cancer Diagnostic to Transform Precision Medicine

Molecular diagnostic tests have long been regarded as the standard for selecting personalized treatments, especially in oncology. However, these tests require physical tissue samples and are often limited by challenges such as low accuracy, long development timelines, restricted scope, and high costs. Now, revolutionary artificial intelligence (AI)-driven diagnostic tests are poised to greatly improve the prediction of patient outcomes and support more precise, personalized treatment strategies.

Ataraxis AI (New York, NY, USA) is pioneering the development of multi-modal AI foundation models and diagnostic tests that forecast the risk of cancer development and predict patient outcomes. These innovations will allow healthcare providers to tailor treatments that are most likely to be effective for individual patients. Ataraxis aims to create diagnostic tests for at least half of the 26 million new cancer patients anticipated globally by 2030. This initiative is set to revolutionize cancer care, offering doctors enhanced insights into patient health and enabling them to provide highly personalized treatment plans, ensuring optimal care for every patient.

To usher in this new era of AI-powered precision medicine, Ataraxis has developed Kestrel, a foundation AI model for digital pathology that surpasses current pathology models. Kestrel uncovers novel features linked to patient outcomes that are often too complex for human experts, including physicians, to fully understand. These features span a wide range of diseases. Leveraging these insights, Ataraxis is developing multi-modal diagnostic tests that are not only highly accurate and applicable to various clinical scenarios but also have an extensive range and can be delivered in a software-like manner. Using Kestrel, Ataraxis has created its first clinical diagnostic test, Ataraxis Breast – the world’s first AI-native prognostic and predictive test for breast cancer, which is the most advanced clinically validated test available.

Ataraxis Breast provides results in just one hour after receiving specimens, using data from existing samples with no need for additional procedures. The test has already shown superior performance compared to standard genomic assays. Initially validated in a multi-site study involving over 7,500 patients from 15 institutions across three continents, Ataraxis Breast has demonstrated that it outperforms current standards in selecting breast cancer treatments. The results revealed that Ataraxis Breast predicts cancer recurrence with 30% greater accuracy than traditional molecular diagnostic assays. Furthermore, it works across all breast cancer subtypes, including those for which current clinical guidelines offer no recommended diagnostic tools.

Related Links:
Ataraxis AI

Visit expo >

New

Gold Member

Chagas Disease Test

CHAGAS Cassette

New

Gold Member

Strep Pneumoniae Rapid Test

Strep Pneumoniae (6503 – 6573)

New

Zonulin ELISA

IDK Zonulin (Serum) ELISA

New

Carcinoembryonic Antigen Test

CEA Test